Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab

References

• Vangeli E, Bakhshi S, Baker A, et al. A systematic review of factors associated with non-adherence to treatment for immune-mediated inflammatory diseases. Adv Ther. 2015;32(11):983–1028.
   PubMed Web of Science ®Google Scholar
• Hunter TM, Boytsov NN, Zhang X, et al. Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014. Rheumatol Int. 2017;37(9):1551–1557.
   PubMed Web of Science ®Google Scholar
• Shivashankar R, Tremaine WJ, Harmsen WS, et al. Incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota from 1970 through 2010. Clin Gastroenterol Hepatol. 2017;15(6):857–863.
   PubMed Web of Science ®Google Scholar
• Kuek A, Hazleman BL, Ostor AJ. Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution. Postgrad Med J. 2007;83(978):251–260.
   PubMed Web of Science ®Google Scholar
• Hanauer SB. The expanding role of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010;7(2):63–64.
   PubMed Web of Science ®Google Scholar
• Janssen Pharmaceutical Companies. REMICADE (infliximab) Highlights of Prescribing Information. 2018. p. 1–21.
   Google Scholar
• Melsheimer R, Geldhof A, Apaolaza I, et al. Remicade® (infliximab): 20 years of contributions to science and medicine. Biologics. 2019;13:139–178.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Biosimilar and Interchangeable Products 2017. [cited 2019 December 17]. Available from: https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products.
   Google Scholar
• Olech E. Biosimilars: rationale and current regulatory landscape. Semin Arthritis Rheum. 2016;45(5 Suppl):S1–S10.
   PubMed Web of Science ®Google Scholar
• Jacobs I, Petersel D, Isakov L, et al. Biosimilars for the treatment of chronic inflammatory diseases: a systematic review of published evidence. BioDrugs. 2016;30(6):525–570.
   PubMed Web of Science ®Google Scholar
• CELLTRION, Inc. INFLECTRA® (infliximab-dyyb) Highlights of Prescribing Information. 2019. p. 1–43.
   Google Scholar
• CELLTRION I. INFLECTRA® (infliximab-dyyb) Highlights of Prescribing Information 2019.
   Google Scholar
• Inc A. AVSOLA (infliximab-axxq) Highlights of Prescribing Information 2019.
   Google Scholar
• Co SB. RENFLEXIS (infliximab-abda) Highlights of Prescribing Information. 2019.
   Google Scholar
• Pharmaceuticals PI. IXIFI (infliximab-qbtx) Highlights of Prescribing Information. 2020.
   Google Scholar
• Teeple A, Ellis LA, Huff L, et al. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States. Curr Med Res Opin. 2019;35(4):611–617.
   PubMed Web of Science ®Google Scholar
• Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (nor-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–2316.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Choe JY, Prodanovic N, et al. Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Ann Rheum Dis. 2018;77(2):234–240.
   PubMed Web of Science ®Google Scholar
• Avouac J, Molto A, Abitbol V, et al. Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: the experience of cochin university hospital, paris, France. Semin Arthritis Rheum. 2018;47(5):741–748.
   PubMed Web of Science ®Google Scholar
• Gentileschi S, Barreca C, Bellisai F, et al. Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases response to: Nikiphorou E, kautiainen H, hannonen P, et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert opin biol ther. 2015;15:1677-1683. Expert Opin Biol Ther. 2016;16(10):1311–1312.
   PubMed Web of Science ®Google Scholar
• Glintborg B, Sorensen IJ, Loft AG, et al. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis. 2017;76(8):1426–1431.
   PubMed Web of Science ®Google Scholar
• Tweehuysen L, van den Bemt BJF, van Ingen IL, et al. Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol. 2018;70(1):60–68.
   PubMed Web of Science ®Google Scholar
• Scherlinger M, Germain V, Labadie C, et al. Switching from originator infliximab to biosimilar CT-P13 in real-life: the weight of patient acceptance. Joint Bone Spine. 2018;85(5):561–567.
   PubMed Web of Science ®Google Scholar
• Reuber K, Kostev K. Prevalence of switching from two anti-TNF biosimilars back to biologic reference products in Germany. Int J Clin Pharmacol Ther. 2019;57(6):323–328.
   PubMed Web of Science ®Google Scholar
• Rezk MF, Pieper B. Treatment outcomes with biosimilars: be aware of the nocebo effect. Rheumatol Ther. 2017;4(2):209–218.
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Jairath V, Mysler E, et al. Nonmedical switching from originators to biosimilars: does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology? Rheumatol Ther. 2020;7(1):35–64.
   PubMed Web of Science ®Google Scholar
• Fitzgerald T, Melsheimer R, Lafeuille MH, et al. Switching and discontinuation patterns among patients stable on originator infliximab who switched to an infliximab biosimilar or remained on originator infliximab. Biologics. 2021;15:1–15.
   PubMed Web of Science ®Google Scholar
• Johnson JAJ, Curtis JR, Pinnell DK, et al. P1570: Infliximab Biosimilar use for Inflammatory Bowel Disease: A National Veterans Affairs Experience. ACG 2020. Annual Scientific Meeting; Virtual2020.
   Google Scholar
• Lund JL, Horvath-Puho E, Komjathine Szepligeti S, et al. Conditioning on future exposure to define study cohorts can induce bias: the case of low-dose acetylsalicylic acid and risk of major bleeding. Clin Epidemiol. 2017;9:611–626.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Yazici Y, Xie L, Ogbomo A, et al. Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab. Biologics. 2018;12:127–134.
   PubMed Web of Science ®Google Scholar
• Phillips K, Juday T, Zhang Q, et al. SAT0172 economic outcomes, treatment patterns, and adverse events and reactions for patients prescribed infliximab or ct-p13 in the Turkish population. Annals Rheumatic Dis. 2017;76(Suppl 2):835.1–835.
   Google Scholar
• Bakalos G, Zintzaras E. Drug discontinuation in studies including a switch from an originator to a biosimilar monoclonal antibody: a systematic literature review. Clin Ther. 2019;41(1):155–173 e13.
   PubMed Web of Science ®Google Scholar
• Ho SL, Niu F, Pola S, et al. Effectiveness of switching from reference product infliximab to Infliximab-Dyyb in patients with inflammatory bowel disease in an integrated healthcare system in the United States: a retrospective, propensity score-matched, non-inferiority cohort study. BioDrugs. 2020;34(3):395–404.
   PubMed Web of Science ®Google Scholar
• Fleischmann RM, Blanco R, Hall S, et al. Switching between Janus kinase inhibitor Upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis. Ann Rheum Dis. 2021;80(4):432–439.
   PubMed Web of Science ®Google Scholar
• Madenidou A, Jeffries A, Varughese S, et al. Switching patients with inflammatory arthritis from etanercept (Enbrel®) to the biosimilar drug, SB4 (Benepali®): a single-centre retrospective observational study in the UK and a review of the literature. MJR. 2019;30(Suppl 1):69–75.
   Google Scholar
• Alten R, Neregard P, Jones H, et al. SAT0161 preliminary real world data on switching patterns between etanercept, its recently marketed biosimilar counterpart and its competitor adalimumab, using Swedish prescription registry. Annals Rheumatic Dis. 2017;76(Suppl 2):831.
   PubMed Web of Science ®Google Scholar
• Teeple A, Ginsburg S, Howard L, et al. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States. Curr Med Res Opin. 2019;35(4):603–609.
   PubMed Web of Science ®Google Scholar
• Boone NW, Liu L, Romberg-Camps MJ, et al. The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol. 2018;74(5):655–661.
   PubMed Web of Science ®Google Scholar
• Mahmmod S, Schultheiss JPD, van Bodegraven AA, et al. Outcome of reverse switching from CT-P13 to originator infliximab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(12):1954–1962.
   PubMed Web of Science ®Google Scholar
• Afzali A, Furtner D, Melsheimer R, et al. The automatic substitution of biosimilars: definitions of interchangeability are not interchangeable. Adv Ther. 2021;38(5):2077–2093.
   PubMed Web of Science ®Google Scholar
• Baker JF, Leonard CE, Lo Re V, 3rd, et al. Biosimilar uptake in academic and veterans health administration settings: Influence of institutional incentives. Arthritis Rheumatol. 2020;72(7):1067–1071.
   PubMed Web of Science ®Google Scholar
• Burk M, Furmaga E, Dong D, et al. Multicenter drug use evaluation of tamsulosin and availability of guidance criteria for nonformulary use in the veterans affairs health system. J Manag Care Pharm. 2004;10(5):423–432.
   PubMedGoogle Scholar
• Gellad WCB, Lowe JC, Donohue JM. Variation in prescription use and spending for lipid-lowering and diabetes medications in the VA healthcare system. Am J Manag Care. 2010;16(10):741–750.
   PubMed Web of Science ®Google Scholar
• Radomski TR, Good CB, Thorpe CT, et al. Variation in formulary management practices within the department of veterans affairs health care system. JMCP. 2016;22(2):114–120.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Marabani M, Wu JJ, et al. The challenges of switching therapies in an evolving multiple biosimilars landscape: a narrative review of current evidence. Adv Ther. 2020;37(11):4491–4518.
   PubMed Web of Science ®Google Scholar
• Mahmmod S, Schultheiss J, Tan A, et al. Reasons for and effectiveness of switching back to originator infliximab after a prior switch to CT-P13 biosimilar. J Crohn's Colitis. 2020;14(Supplement_1):S316–S317.
   Google Scholar
• Pernes TPM, Khan N, Crescenz MJ, P1597 (S0792). The Safety of Switching From Originator Infliximab or Biosimilar CT-P. 13 to SB2 Among a Nationwide Cohort of Inflammatory Bowel Disease Patients. ACG 2020 Annual Scientific Meeting; Virtual; 2020.
   Google Scholar
• Moorkens E, Godman B, Huys I, et al. The expiry of Humira® market exclusivity and the entry of adalimumab biosimilars in Europe: an overview of pricing and national policy measures. Front Pharmacol. 2020;11:591134.
   PubMed Web of Science ®Google Scholar
• Jensen TB, Kim SC, Jimenez-Solem E, et al. Shift from adalimumab originator to biosimilars in Denmark. JAMA Intern Med. 2020;180(6):902–903.
   PubMed Web of Science ®Google Scholar
• Dutta B, Huys I, Vulto AG, et al. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price!. BioDrugs. 2020;34(2):159–170.
   PubMed Web of Science ®Google Scholar
• Kim Y, Kwon HY, Godman B, et al. Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: budget savings or market expansion across countries? Front Pharmacol. 2020;11:970.
   PubMed Web of Science ®Google Scholar
• Brown CN, McCann E. Cost of switching from an originator biologic (Remicade) to a biosimilar. Value in Health. 2016;19(7):A581.
   Web of Science ®Google Scholar
• Bhat S, Qazi T. Switching from infliximab to biosimilar in inflammatory bowel disease: a review of existing literature and best practices. Crohn's Colitis 360. 2021;3(1):1–6.
   Google Scholar
• Liu Y, Yang M, Garg V, et al. Economic impact of non-medical switching from originator biologics to biosimilars: a systematic literature review. Adv Ther. 2019;36(8):1851–1877.
   PubMed Web of Science ®Google Scholar
• Gibofsky A, Skup M, Yang M, et al. Short-term costs associated with non-medical switching in autoimmune conditions. Clin Exp Rheumatol. 2019;37(1):97–105.
   PubMed Web of Science ®Google Scholar
• San-Juan-Rodriguez A, Gellad WF, Good CB, et al. Trends in list prices, net prices, and discounts for originator biologics facing biosimilar competition. JAMA Netw Open. 2019;2(12):e1917379.
   PubMed Web of Science ®Google Scholar
• Hernandez I, Good CB, Shrank WH, et al. Trends in Medicaid Prices, Market Share, and Spending on Long-Acting Insulins, 2006–2018. JAMA. 2019;321(16):1627–1629.
   Google Scholar
• Yazdany J, Dudley RA, Lin GA, et al. Out-of-Pocket Costs for Infliximab and its biosimilar for rheumatoid arthritis under Medicare part D. JAMA. 2018;320(9):931–933.
   Google Scholar
• El-Gabalawy H, Guenther LC, Bernstein CN. Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities. J Rheumatol Suppl. 2010;85:2–10.
   PubMedGoogle Scholar
• Howe CJ, Cole SR, Lau B, et al. Selection bias due to loss to follow up in Cohort studies. Epidemiology. 2016;27(1):91–97.
   PubMed Web of Science ®Google Scholar